Abstract:ObjectiveTo compare the curative effect of KRAS wildtype metastatic colorectal cancer patients treated with either single agent panitumumab or combination therapy with cetuximab and irinotecan. MethodsUsing the random number table method (concealment of allocation), the study enrolled 35 patients with KRAS wildtype metastatic colorectal cancer, who had received epidermal growth factor receptor inhibitor, either panitumumab (20 cases) or combination cetuximabirinotecan (15 cases). The differences of curative effect between groups were assessed by statistical analysis. ResultsFive (25.0%) panitumumab and four (26.7%) cetuximabirinotecantreated patients had partial response, and the difference was not statistically significant (P=0.64). Median overall survival was 8.3 months for the panitumumab group and 8.5 months for the cetuximabirinotecan group (χ2=1.161, P=0.13). Multivariate analysis demonstrated that survival outcomes were similar regardless of the therapy selected and the difference was not statistically significant (HR=1.17, 95%CI: 0.682.04, χ2=1.01, P=0.47). 95% patients who received panitumumab and all cetuximabirinotecantreated patients (100%) experienced treatmentrelated adverse events (P=0.72). ConclusionThe drug therapy of panitumumab and cetuximabirinotecan treatment were similar to KRAS wildtype metastatic colorectal cancer patients and can be reasonable used as thirdline treatment options for patients with chemoresistant metastatic colorectal neoplasms.

Key words:Receptor, epidermal growth factor,Colorectal neoplasms,Drug therapy